ER+HER2- breast cancer – Patient Worthy

Source: Pixabay

Updated Phase 1/2 Data Highlights Vepdegestrant Benefits for ER+ HER2- Breast Cancer

Post author:Jessica Lynn
Post published:December 8, 2023
Post category:Breast Cancer

A Phase 1/2 clinical trial sought to evaluate the potential of vepdegestrant as a therapeutic option for heavily pretreated individuals with estrogen receptor-positive (ER+) and HER2 negative (HER2-) advanced…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More